Which has preferable valuation and earnings, PSTV or MBAI?

Plus Therapeutics is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A Check-Cap N/A N/A $4.14M -$2.01 N/A

Does the media favor PSTV or MBAI?

In the previous week, Plus Therapeutics had 1 more articles in the media than Check-Cap. MarketBeat recorded 3 mentions for Plus Therapeutics and 2 mentions for Check-Cap. Check-Cap's average media sentiment score of 1.16 beat Plus Therapeutics' score of 1.07 indicating that Check-Cap is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PETV or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PETV or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Check-Cap's return on equity of 0.00% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% Check-Cap N/A N/A N/A

Does the media favor PETV or MBAI?

In the previous week, Check-Cap had 1 more articles in the media than PetVivo. MarketBeat recorded 2 mentions for Check-Cap and 1 mentions for PetVivo. Check-Cap's average media sentiment score of 1.16 beat PetVivo's score of 0.00 indicating that Check-Cap is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MBAI or CTSO?

Cytosorbents has a consensus target price of $5.38, indicating a potential upside of 1,393.06%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MBAI or CTSO more profitable?

Check-Cap has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Check-Cap's return on equity of 0.00% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Cytosorbents -31.85% -235.57% -37.88%

Does the media prefer MBAI or CTSO?

In the previous week, Check-Cap and Check-Cap both had 2 articles in the media. Check-Cap's average media sentiment score of 1.16 beat Cytosorbents' score of 0.94 indicating that Check-Cap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MBAI or LFWD?

Lifeward has a consensus target price of $10.00, indicating a potential upside of 41.84%. Given Lifeward's stronger consensus rating and higher probable upside, analysts clearly believe Lifeward is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lifeward 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is MBAI or LFWD more profitable?

Check-Cap has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Check-Cap's return on equity of 0.00% beat Lifeward's return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Lifeward -123.66% -243.14% -97.39%

Does the media prefer MBAI or LFWD?

In the previous week, Check-Cap and Check-Cap both had 2 articles in the media. Check-Cap's average media sentiment score of 1.16 beat Lifeward's score of 0.94 indicating that Check-Cap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifeward 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MBAI or RVP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Check-Cap (MBAI) Competitors

$1.10 -0.07 (-5.98%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.10 0.00 (0.00%)

As of 07/24/2026 06:59 PM Eastern

Compare

MBAI vs. PSTV, PETV, CTSO, LFWD, and RVP

Should you buy Check-Cap stock or one of its competitors? MarketBeat compares Check-Cap with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Check-Cap include Plus Therapeutics (PSTV), PetVivo (PETV), Cytosorbents (CTSO), Lifeward (LFWD), and Retractable Technologies (RVP). These companies are all part of the "medical equipment" industry.

How does Check-Cap compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Plus Therapeutics is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.01	N/A

Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Plus Therapeutics had 1 more articles in the media than Check-Cap. MarketBeat recorded 3 mentions for Plus Therapeutics and 2 mentions for Check-Cap. Check-Cap's average media sentiment score of 1.16 beat Plus Therapeutics' score of 1.07 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Plus Therapeutics presently has a consensus target price of $56.40, suggesting a potential upside of 1,372.58%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Plus Therapeutics is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Check-Cap's return on equity of 0.00% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Check-Cap	N/A	N/A	N/A

Summary

Plus Therapeutics and Check-Cap tied by winning 7 of the 14 factors compared between the two stocks.

How does Check-Cap compare to PetVivo?

PetVivo (NASDAQ:PETV) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 10.8% of PetVivo shares are owned by insiders. Comparatively, 0.5% of Check-Cap shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Check-Cap's return on equity of 0.00% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Check-Cap	N/A	N/A	N/A

Check-Cap has lower revenue, but higher earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	25.88	-$10.95M	-$0.38	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.01	N/A

In the previous week, Check-Cap had 1 more articles in the media than PetVivo. MarketBeat recorded 2 mentions for Check-Cap and 1 mentions for PetVivo. Check-Cap's average media sentiment score of 1.16 beat PetVivo's score of 0.00 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PetVivo has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Summary

Check-Cap beats PetVivo on 8 of the 13 factors compared between the two stocks.

How does Check-Cap compare to Cytosorbents?

Check-Cap (NASDAQ:MBAI) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Cytosorbents has a consensus target price of $5.38, indicating a potential upside of 1,393.06%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Check-Cap has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Check-Cap's return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Cytosorbents	-31.85%	-235.57%	-37.88%

In the previous week, Check-Cap and Check-Cap both had 2 articles in the media. Check-Cap's average media sentiment score of 1.16 beat Cytosorbents' score of 0.94 indicating that Check-Cap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by company insiders. Comparatively, 7.8% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Check-Cap has higher earnings, but lower revenue than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.01	N/A
Cytosorbents	$37.06M	0.61	-$8.20M	-$0.19	N/A

Check-Cap has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Summary

Cytosorbents beats Check-Cap on 8 of the 14 factors compared between the two stocks.

How does Check-Cap compare to Lifeward?

Check-Cap (NASDAQ:MBAI) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 1.5% of Lifeward shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Check-Cap has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Check-Cap has higher earnings, but lower revenue than Lifeward. Check-Cap is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.01	N/A
Lifeward	$22.03M	0.90	-$19.91M	-$19.66	N/A

In the previous week, Check-Cap and Check-Cap both had 2 articles in the media. Check-Cap's average media sentiment score of 1.16 beat Lifeward's score of 0.94 indicating that Check-Cap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifeward	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Check-Cap has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Check-Cap's return on equity of 0.00% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Lifeward	-123.66%	-243.14%	-97.39%

Lifeward has a consensus target price of $10.00, indicating a potential upside of 41.84%. Given Lifeward's stronger consensus rating and higher probable upside, analysts clearly believe Lifeward is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Check-Cap and Lifeward tied by winning 7 of the 14 factors compared between the two stocks.

How does Check-Cap compare to Retractable Technologies?

Check-Cap (NASDAQ:MBAI) and Retractable Technologies (NYSE:RVP) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are held by institutional investors. 0.5% of Check-Cap shares are held by insiders. Comparatively, 59.5% of Retractable Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Check-Cap has a net margin of 0.00% compared to Retractable Technologies' net margin of -41.11%. Check-Cap's return on equity of 0.00% beat Retractable Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Retractable Technologies	-41.11%	-17.15%	-9.33%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Check-Cap has higher earnings, but lower revenue than Retractable Technologies. Retractable Technologies is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.01	N/A
Retractable Technologies	$37.15M	0.55	-$7.01M	-$0.21	N/A

Check-Cap has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Retractable Technologies has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

In the previous week, Check-Cap had 2 more articles in the media than Retractable Technologies. MarketBeat recorded 2 mentions for Check-Cap and 0 mentions for Retractable Technologies. Check-Cap's average media sentiment score of 1.16 beat Retractable Technologies' score of 0.00 indicating that Check-Cap is being referred to more favorably in the media.

Company	Overall Sentiment
Check-Cap	Positive
Retractable Technologies	Neutral

Summary

Check-Cap beats Retractable Technologies on 8 of the 13 factors compared between the two stocks.

Get Check-Cap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBAI vs. The Competition

Export

Metric	Check-Cap	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$8.53M	$3.03B	$7.24B	$12.26B
Dividend Yield	N/A	N/A	40.99%	9.79%
P/E Ratio	-0.55	21.41	23.62	23.64
Price / Sales	N/A	254.21	160.99	76.82
Price / Cash	2.06	8.66	165.01	59.64
Price / Book	2.34	5.32	12.77	6.07
Net Income	$4.14M	$23.43M	$120.21M	$331.99M
7 Day Performance	10.00%	-4.57%	-0.98%	-0.63%
1 Month Performance	-0.90%	-8.25%	-2.00%	-2.00%
1 Year Performance	N/A	2.05%	9.75%	13.62%

Check-Cap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBAI Check-Cap	0.7835 of 5 stars	$1.10 -6.0%	N/A	N/A	$8.53M	N/A	N/A	80	News Coverage Positive News Analyst Forecast
PSTV Plus Therapeutics	2.6469 of 5 stars	$3.82 -2.6%	$56.40 +1,376.4%	-74.3%	$26.28M	$5.21M	N/A	20	Positive News
PETV PetVivo	N/A	$0.69 -10.1%	N/A	-10.0%	$26.04M	$1.05M	N/A	20	Gap Up High Trading Volume
CTSO Cytosorbents	2.4863 of 5 stars	$0.38 -3.0%	$5.38 +1,307.4%	-64.0%	$24.00M	$37.06M	N/A	220
LFWD Lifeward	1.9291 of 5 stars	$7.34 +1.2%	$10.00 +36.2%	-28.9%	$20.63M	$22.03M	N/A	60	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBAI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Check-Cap (MBAI) Competitors

MBAI vs. PSTV, PETV, CTSO, LFWD, and RVP

How does Check-Cap compare to Plus Therapeutics?

Summary

How does Check-Cap compare to PetVivo?

Summary

How does Check-Cap compare to Cytosorbents?

Summary

How does Check-Cap compare to Lifeward?

Summary

How does Check-Cap compare to Retractable Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBAI vs. The Competition

Check-Cap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Check-Cap (MBAI) Competitors

MBAI vs. PSTV, PETV, CTSO, LFWD, and RVP

How does Check-Cap compare to Plus Therapeutics?

Which has preferable valuation and earnings, PSTV or MBAI?

Which has more risk and volatility, PSTV or MBAI?

Do insiders & institutionals believe in PSTV or MBAI?

Does the media favor PSTV or MBAI?

Do analysts rate PSTV or MBAI?

Is PSTV or MBAI more profitable?

Summary

How does Check-Cap compare to PetVivo?

Do institutionals and insiders believe in PETV or MBAI?

Do analysts rate PETV or MBAI?

Is PETV or MBAI more profitable?

Which has better earnings and valuation, PETV or MBAI?

Does the media favor PETV or MBAI?

Which has more volatility and risk, PETV or MBAI?

Summary

How does Check-Cap compare to Cytosorbents?

Do analysts rate MBAI or CTSO?

Is MBAI or CTSO more profitable?

Does the media prefer MBAI or CTSO?

Do insiders and institutionals have more ownership in MBAI or CTSO?

Which has better valuation and earnings, MBAI or CTSO?

Which has more volatility & risk, MBAI or CTSO?

Summary

How does Check-Cap compare to Lifeward?

Do insiders & institutionals believe in MBAI or LFWD?

Which has more risk & volatility, MBAI or LFWD?

Which has stronger valuation and earnings, MBAI or LFWD?

Does the media prefer MBAI or LFWD?

Is MBAI or LFWD more profitable?

Do analysts rate MBAI or LFWD?

Summary

How does Check-Cap compare to Retractable Technologies?

Do institutionals & insiders have more ownership in MBAI or RVP?

Is MBAI or RVP more profitable?

Do analysts recommend MBAI or RVP?

Which has stronger valuation and earnings, MBAI or RVP?

Which has more risk and volatility, MBAI or RVP?

Does the media favor MBAI or RVP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBAI vs. The Competition

Check-Cap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools